NTRA Stock Price Today (September 2026) — Natera, Inc. Analysis & Key Metrics 2026-09-03
Natera, Inc. (NTRA) is trading at $327.67, up 0.77% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $282.86 (-13.7% upside).
- Volatility remains elevated (26.02% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (37.70% YoY) alongside significant competitive pressures.
NTRA Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Natera, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $46.18B
P/E Ratio
Forward P/E: -3609.42
Revenue Growth
Year over Year
Analyst Target
+-13.7% upside potential
Key Investor Questions About NTRA
What investors need to know before buying
Based on current market data, NTRA presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 59.91)
- Fundamentals say: Caution warranted (high leverage concerns)
NTRA's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTRA investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $238.49M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, NTRA stock traded between $157.43 and $343.18—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.02% annualized volatility and β=1.21, the stock exhibits high sensitivity to market moves—making NTRA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
3 Momentum Stocks to Own for Decades
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
The billionaire has good reasons to like this genetic testing leader.
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.
How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion
Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the same time, Duquesne Family Office significantly increased its position in Natera, making the diagnostics company its largest healthcare holding and underscoring rising institutional interest in its MRD and medtech platform. Now we’ll explore how this...
Natera (NTRA) Supplies MRD Assay For Phase 1 Skin Cancer Immunotherapy Trial
Natera (NasdaqGS:NTRA) announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers. The Latitude assay will be used to monitor minimal residual disease and treatment response in patients receiving Kupando's investigational therapy. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumor types. This kind of cancer trial...
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Duquesne Family Office has beefed up its healthcare holdings.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
What Is Really Moving Tempus AI Stock Right Now?
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.
Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.
Explore More Analysis for NTRA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Natera, Inc.
Natera, Inc. (NTRA) is currently trading at $327.67. The RSI (14-day) is at 59.9, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $282.86 implies 13.7% downside from current levels. Volatility is moderate at 26.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Natera, Inc. (NTRA): The trailing P/E ratio is -244.53, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -3609.42, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 25.84. Price-to-Sales is 17.45. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering NTRA, the consensus price target is $282.86. This represents a 13.7% downside from the current price of $327.67. The range spans from a low target of $193.00 to a high target of $330.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Natera, Inc. (NTRA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Natera, Inc. (NTRA) investors include: 1. Moderate volatility (26.0% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Natera, Inc.'s (NTRA) current debt and financial health profile: Total debt stands at $238.49M. The debt-to-equity ratio is 13.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.00, indicating strong short-term liquidity. The quick ratio is 2.74. The company holds $1.09B in cash and equivalents. Free cash flow is positive at $104.03M, providing a cushion for debt servicing and shareholder returns.